Novo Nordisk Halts Heart Failure Drug Trials, Advances Wegovy for Children

Novo Nordisk terminated two Phase 3 trials of ziltivekimab for heart failure with inflammation due to futility, a setback in its cardiovascular pipeline. Concurrently, the company is advancing Wegovy for pediatric use, signaling a strategic pivot toward obesity indications. The heart failure failure may pressure near-term growth expectations, while pediatric expansion offers a new market opportunity.